AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Yatra Online Posts Q1 Growth Amid Travel Disruptions
ByAinvest
Friday, Aug 8, 2025 9:38 pm ET1min read
Morgan Stanley analyst Judah Frommer initiated coverage on COMPASS Pathways with a Buy rating and a $10.00 price target. The company's shares opened at $4.45. The analyst consensus on COMPASS Pathways is a Strong Buy with an average price target of $15.10, representing a 239.33% upside. CMPS market cap is $408M and has a P/E ratio of -2.38.
Morgan Stanley analyst Judah Frommer has initiated coverage on Compass Pathways (CMPS) with a Buy rating and a price target of $10.00. The company's shares opened at $4.45 on July 2, 2025. The analyst consensus on Compass Pathways is a Strong Buy with an average price target of $15.10, representing a 239.33% upside. Compass Pathways has a market capitalization of $408 million and a P/E ratio of -2.38 [2].Compass Pathways is dedicated to accelerating patient access to evidence-based innovation in mental health. The company's lead product candidate, COMP360, is a psilocybin treatment for treatment-resistant depression (TRD). The company has published positive phase 2 data for PTSD and is conducting pivotal trials for TRD. Compass Pathways has a cash position of $222 million at June 30, 2025 [2].
Treatment-resistant depression (TRD) affects millions in the U.S., with approximately 9 million patients failing to respond to at least two antidepressant regimens. TRD patients are disproportionately impacted compared to non-TRD major depressive disorder (MDD) patients, experiencing longer depressive episodes, greater work time loss, and increased risks of mortality [2].
The analyst consensus reflects optimism about Compass Pathways' potential to revolutionize mental health care. The company's pipeline and positive clinical trial results have garnered significant attention from investors. However, the high price target and negative P/E ratio indicate that the market expects substantial growth and potential for significant upside.
Investors should carefully consider Compass Pathways' unique position in the mental health market and the potential risks associated with the biotechnology sector. The company's strong clinical data and experienced management team position it well to capitalize on the growing demand for innovative mental health solutions.
References:
[1] https://www.marketbeat.com/instant-alerts/morgan-stanley-increases-duolingo-nasdaqduol-price-target-to-50000-2025-08-07/
[2] https://www.marketscreener.com/news/compass-pathways-investor-presentation-august-2025-ce7c5edfd18ffe24
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet